• Home
  • Contributors
  • Glossary
  • Subscribe

Bioasis Technologies Inc.

The Science of Melanotransferrin (p97)

From the category archives:

Parkinson’s

Sinemet Shortage Leaves Patients in the Lurch

by Mahesh on July 9, 2010

Impact Of Alzheimer’s On Families Reveals Dire Need For Efficient Caregiving

by Mahesh on June 18, 2010

Consortium Will Share Clinical Trials Data To Aid Alzheimer’s Effort

by Mahesh on June 17, 2010

The Difference Between Alzheimer’s and Dementia

by Henry on May 21, 2010

Global Shortage Of Parkinson’s Drug Shows Vulnerability On Neurological Disease Front

by Mahesh on April 2, 2010

Neurological Diseases And Health Reform – How It All Comes Together

by Mahesh on March 25, 2010

BioPharma Profiles In Neuroscience – Biogen Idec

by Mahesh on March 10, 2010

Alzheimer’s Drug Dimebon Helps Huntington’s Disease

by Henry on February 15, 2010

News about the Alzheimer’s Eye Exam

by Henry on January 25, 2010

Biotech CEOs Present An Optimisitic Outlook At The JP Morgan Healthcare Conference

by Mahesh on January 22, 2010

← Previous Entries

  • Pages

    • Contributors
    • Glossary
    • Robin (Rob) B. Hutchison, Chairman & CEO
  • Recent Posts

    • Sleep Disorder Predicts Dementia?
    • Controversy-plagued Genzyme Refuses Sanofi Acquisition
    • Mental Exercises Affect Alzheimer’s Disease
    • Blood-Brain Barrier Carriers – the Next Frontier for CNS Diseases?
    • What If Amyloid Actually Protected The Brain?
  • Categories

    • ADDL (1)
    • age-related neurodegenerative disease (150)
    • Alzheimer's Research (194)
    • amyloid beta deposits/plaques (64)
    • amyloid protein vaccination (4)
    • antidepressants (4)
    • axon deterioration (53)
    • BioAsis (106)
    • biosecurity (1)
    • biosimilar therapies (23)
    • biotechnology (151)
    • bioterrorism (1)
    • Blood Brain Barrier (53)
    • CEO (2)
    • cholinergic effects (1)
    • chronic neurological diseases (81)
    • Citizen Petition (4)
    • dementia (71)
    • diabetes (5)
    • DNA (5)
    • Dr. Wilf Jefferies (3)
    • FDA (14)
    • Frontotemporal Dementia (19)
    • Genentech (9)
    • Health reform (17)
    • Huntington's Disease (11)
    • Huntington’s Disease (5)
    • immunotherapy (1)
    • LDT (1)
    • Lewy Body Variant (5)
    • Melanotransferrin (64)
    • mental illness (51)
    • MOCA (2)
    • Neurological Diseases (163)
    • neurological disorders (68)
    • New Studies (18)
    • Not-for-Profit Organisations (9)
    • P97 (81)
    • Parkinson's (22)
    • Parkinson's Disease (32)
    • Parkinson’s (8)
    • personalized medicine (7)
    • Pfizer (36)
    • Pharma (31)
    • prescription medicine (13)
    • research cutbacks (31)
    • Research tools (4)
    • SEB (2)
    • Subsequent Entry Biologics (2)
    • tau tangles (30)
    • team members (3)
    • Uncategorized (29)
    • Unconventional treatments (4)
    • Vascular Dementia (23)
    • Wyeth (21)
  • Recent Comments

    • Blood-Brain Barrier Carriers - the Next Frontier for CNS Diseases? on The Blood-Brain Barrier: A Major Hurdle For Neurological Drug Delivery
    • What If Amyloid Actually Protected the Brain? on Will Anti-Amyloid Failures Change Pharma Approach?
    • Will Anti-Amyloid Failures Failures Change Pharma Approach? on Bapineuzumab’s Phase II Results Published – AD Drug Fails Expectations
    • Willa Zavala on Be Careful of Some Home Remedies for Alzheimer’s Disease
    • Biomarker Tests Can Revolutionize Alzheimer's Diagnosis and Treatment on biOasis CEO Rob Hutchison provides shareholder update
  • Archives

    • September 2010 (5)
    • August 2010 (17)
    • July 2010 (19)
    • June 2010 (18)
    • May 2010 (16)
    • April 2010 (17)
    • March 2010 (17)
    • February 2010 (15)
    • January 2010 (15)
    • December 2009 (16)
    • November 2009 (16)
    • October 2009 (17)
    • September 2009 (18)
    • August 2009 (18)
    • July 2009 (18)
    • June 2009 (15)
    • May 2009 (13)
    • April 2009 (13)
    • March 2009 (10)
    • February 2009 (16)
    • January 2009 (4)
    • September 2008 (1)
  • Categories

    • ADDL
    • age-related neurodegenerative disease
    • Alzheimer's Research
    • amyloid beta deposits/plaques
    • amyloid protein vaccination
    • antidepressants
    • axon deterioration
    • BioAsis
    • biosecurity
    • biosimilar therapies
    • biotechnology
    • bioterrorism
    • Blood Brain Barrier
    • CEO
    • cholinergic effects
    • chronic neurological diseases
    • Citizen Petition
    • dementia
    • diabetes
    • DNA
    • Dr. Wilf Jefferies
    • FDA
    • Frontotemporal Dementia
    • Genentech
    • Health reform
    • Huntington's Disease
    • Huntington’s Disease
    • immunotherapy
    • LDT
    • Lewy Body Variant
    • Melanotransferrin
    • mental illness
    • MOCA
    • Neurological Diseases
    • neurological disorders
    • New Studies
    • Not-for-Profit Organisations
    • P97
    • Parkinson's
    • Parkinson's Disease
    • Parkinson’s
    • personalized medicine
    • Pfizer
    • Pharma
    • prescription medicine
    • research cutbacks
    • Research tools
    • SEB
    • Subsequent Entry Biologics
    • tau tangles
    • team members
    • Uncategorized
    • Unconventional treatments
    • Vascular Dementia
    • Wyeth

Get smart with the Thesis WordPress Theme from DIYthemes.

WordPress Admin